(Q64377012)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

main subject

phase I clinical trial

1 reference

Nemunaitis J

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Senzer N

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Sarmiento S

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Zhang YA

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Arzaga R

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Sands B

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Maples P

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Tong AW

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

17 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

885-893

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7701080

3 January 2020

exact match

0 references

cites work

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Measurement of cytokines by bioassays: theory and application

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701080

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7701080

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17704755%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference